Update your tester profile Login
  • Register with Our Database

    Get started on the volunteer process by registering your basic information with our database. This information is provided to help us determine your eligibility for current and future studies. We will not share or sell this info with any third party. 

    Thanks for your interest, you'll find the intake form here

  • Study 1415: Healthy Male and Female Particpants

    Research Purpose: Study 1415 is designed to evaluate an investigational drug being developed for the treatment of certain types of inflammatory conditions. A single dose of the investigational drug will be given as a subcutaneous injection (just under the skin) and will be compared to similar versions of the drug which are approved to be prescribed in the U.S. and Europe (adalimumab/Humira®).  The following will be evaluated:

    • How quickly the body process and eliminates the investigational drug compared to the U.S and E.U. approved versions
    • The safety/tolerability of the investigational drug compared to the U.S and E.U. approved versions
    • The body’s immune response to the investigational drug compared to the U.S and E.U. approved versions

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women are allowed to participate

    Age

    18-45 years

    Body Mass Index (BMI)

    19 and 30.5

    Weight

    Greater than 132 pounds

    Tobacco/Nicotine Use

    No tobacco/nicotine 24 hours prior to in-house stay or while at the research unit.  Use of tobacco/nicotine products at all other times during the study is allowed.

    Drug Testing

    Must test negative for drugs of abuse. 

    Alcohol/Drug Abuse History

    No history of drug or alcohol abuse within 5 year of the screening appointment.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    No required regular use of any prescription medications, non-prescription medications, vitamins, or herbal supplements not listed below

    Allowed Medications

    Acetaminophen and prescribed/stable hormonal birth control are allowed.

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 10 ½ weeks. 

    Inpatient Stays

    • Participants will admit for an inpatient stay at Prism Clinical Research 1 time.
    • The inpatient stay will last approximately 8 ½ days (8 overnights)

    Outpatient Visits

    • There are at total of 9 outpatient visits
    • The outpatient visits will last between approximately 1-2 hours

     Compensation: Up to $2950.00

  • Study 1416: Healthy Male and Female Participants

    Research Purpose: Study 1416 is designed to evaluate an investigational drug being developed for the treatment of certain types of skin conditions. Participants will receive one of two different formulations of the investigational drug which will be given one time as a subcutaneous injection (just under the skin).  The following will be evaluated and compared:

    • How quickly the body processes and eliminates each the different investigational drug formulations.
    • The safety/tolerability of the different investigational drug formulations.

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women are allowed to participate

    Age

    18-65 years

    Weight

    Between 154-198 pounds

    Tobacco/Nicotine Use

    No use of tobacco/nicotine containing products while at Prism.  Use of tobacco/nicotine at all other times is allowed. 

    Drug Testing

    Must test negative for drugs of abuse. 

    Alcohol/Drug Abuse History

    No history of drug or alcohol abuse.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    No required regular use of any prescription medications, non-prescription medications not listed below

    Allowed Medications

    Prescribed hormonal birth control, low dose aspirin, vitamins, and nutritional supplements are allowed

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 8 ½ weeks. 

    Inpatient Stay

    • Participants will admit for an inpatient stay at Prism Clinical Research 1 time.
    • The inpatient stay will last approximately 24 hours

    Outpatient Visits

    • There are at total of  11 outpatient visits
    • The outpatient visits will last between approximately 30-60 minutes

     

    Compensation: Up to $1,775.00

  • Study 1421: Male and Female (of Non-Child Bearing Potential) Participants with High Cholesterol who are Otherwise in Good General Health

    Research Purpose: Study 1421 is designed to evaluate an investigational drug being developed for the treatment of high cholesterol. A single dose of the investigational drug will be given as a subcutaneous injection (just under the skin) via autoinjection pen or a traditional syringe.  The following will be evaluated:

    • How quickly the body process and eliminates the investigational drug when administered through each injection method
    • The safety/tolerability of the investigational drug when administered through each injection method
    • Any changes to LDL cholesterol levels after the investigational drug is administered through each injection method.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women are allowed to participate only if they are postmenopausal or surgically sterilized by hysterectomy, tubal ligation, or bilateral oophorectomy

    Age

    18-65 years

    Body Mass Index (BMI)

    18-32 kg/m²

    Tobacco/Nicotine Use

    Less than 10 cigarettes (or nicotine equivalent) a day in the month prior to the study until completion of the study.  No nicotine use while at Prism.

    Drug Testing

    Must test negative for drugs of abuse. 

    Alcohol/Drug Abuse History

    No history of drug or alcohol abuse within 12 months prior to the start of the study

    Health History

    Must have LDL cholesterol levels between 100-190 and triglycerides ≤ 400; must otherwise be in good general health.

    Restricted Medications

    No use of prescription or over the counter medications or supplements known to affect lipid levels within 30 days prior to the start of the study

    Allowed Medications

    Acetaminophen, prescribed/stable thyroid, and topical medications are allowed.  Other medications may be approved on a case by case basis.

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 8 ½ weeks. 

    Inpatient Stays

    • Participants will admit for an inpatient stay at Prism Clinical Research 1 time.
    • The inpatient stay will last approximately 30 hours (1 overnight)

    Outpatient Visits

    • There are at total of 13 outpatient visits
    • The outpatient visits will last between approximately 30 minuts with the exception of the final visit which will last approximately 90 minutes.

     

    Compensation: Up to $1500.00

Current Studies

Contact a Recruiter

  • Kevin Fitzgerald
    651-289-2098 Email Me

    Recruiter extaordinaire.

  • Molly Hair
    651-289-2096 Email Me
  • Kerry Bunkers
    651-289-2097 Email Me

    Recruiter extraordinaire! 

     

  • Andy Halverson
    651-724-8399 Email Me
  • Register with Our Database

    Get started on the volunteer process by registering your basic information with our database. This information is provided to help us determine your eligibility for current and future studies. We will not share or sell this info with any third party. 

    Thanks for your interest, you'll find the intake form here

  • Study 1415: Healthy Male and Female Particpants

    Research Purpose: Study 1415 is designed to evaluate an investigational drug being developed for the treatment of certain types of inflammatory conditions. A single dose of the investigational drug will be given as a subcutaneous injection (just under the skin) and will be compared to similar versions of the drug which are approved to be prescribed in the U.S. and Europe (adalimumab/Humira®).  The following will be evaluated:

    • How quickly the body process and eliminates the investigational drug compared to the U.S and E.U. approved versions
    • The safety/tolerability of the investigational drug compared to the U.S and E.U. approved versions
    • The body’s immune response to the investigational drug compared to the U.S and E.U. approved versions

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women are allowed to participate

    Age

    18-45 years

    Body Mass Index (BMI)

    19 and 30.5

    Weight

    Greater than 132 pounds

    Tobacco/Nicotine Use

    No tobacco/nicotine 24 hours prior to in-house stay or while at the research unit.  Use of tobacco/nicotine products at all other times during the study is allowed.

    Drug Testing

    Must test negative for drugs of abuse. 

    Alcohol/Drug Abuse History

    No history of drug or alcohol abuse within 5 year of the screening appointment.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    No required regular use of any prescription medications, non-prescription medications, vitamins, or herbal supplements not listed below

    Allowed Medications

    Acetaminophen and prescribed/stable hormonal birth control are allowed.

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 10 ½ weeks. 

    Inpatient Stays

    • Participants will admit for an inpatient stay at Prism Clinical Research 1 time.
    • The inpatient stay will last approximately 8 ½ days (8 overnights)

    Outpatient Visits

    • There are at total of 9 outpatient visits
    • The outpatient visits will last between approximately 1-2 hours

     Compensation: Up to $2950.00

  • Study 1416: Healthy Male and Female Participants

    Research Purpose: Study 1416 is designed to evaluate an investigational drug being developed for the treatment of certain types of skin conditions. Participants will receive one of two different formulations of the investigational drug which will be given one time as a subcutaneous injection (just under the skin).  The following will be evaluated and compared:

    • How quickly the body processes and eliminates each the different investigational drug formulations.
    • The safety/tolerability of the different investigational drug formulations.

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women are allowed to participate

    Age

    18-65 years

    Weight

    Between 154-198 pounds

    Tobacco/Nicotine Use

    No use of tobacco/nicotine containing products while at Prism.  Use of tobacco/nicotine at all other times is allowed. 

    Drug Testing

    Must test negative for drugs of abuse. 

    Alcohol/Drug Abuse History

    No history of drug or alcohol abuse.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    No required regular use of any prescription medications, non-prescription medications not listed below

    Allowed Medications

    Prescribed hormonal birth control, low dose aspirin, vitamins, and nutritional supplements are allowed

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 8 ½ weeks. 

    Inpatient Stay

    • Participants will admit for an inpatient stay at Prism Clinical Research 1 time.
    • The inpatient stay will last approximately 24 hours

    Outpatient Visits

    • There are at total of  11 outpatient visits
    • The outpatient visits will last between approximately 30-60 minutes

     

    Compensation: Up to $1,775.00

  • Study 1421: Male and Female (of Non-Child Bearing Potential) Participants with High Cholesterol who are Otherwise in Good General Health

    Research Purpose: Study 1421 is designed to evaluate an investigational drug being developed for the treatment of high cholesterol. A single dose of the investigational drug will be given as a subcutaneous injection (just under the skin) via autoinjection pen or a traditional syringe.  The following will be evaluated:

    • How quickly the body process and eliminates the investigational drug when administered through each injection method
    • The safety/tolerability of the investigational drug when administered through each injection method
    • Any changes to LDL cholesterol levels after the investigational drug is administered through each injection method.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women are allowed to participate only if they are postmenopausal or surgically sterilized by hysterectomy, tubal ligation, or bilateral oophorectomy

    Age

    18-65 years

    Body Mass Index (BMI)

    18-32 kg/m²

    Tobacco/Nicotine Use

    Less than 10 cigarettes (or nicotine equivalent) a day in the month prior to the study until completion of the study.  No nicotine use while at Prism.

    Drug Testing

    Must test negative for drugs of abuse. 

    Alcohol/Drug Abuse History

    No history of drug or alcohol abuse within 12 months prior to the start of the study

    Health History

    Must have LDL cholesterol levels between 100-190 and triglycerides ≤ 400; must otherwise be in good general health.

    Restricted Medications

    No use of prescription or over the counter medications or supplements known to affect lipid levels within 30 days prior to the start of the study

    Allowed Medications

    Acetaminophen, prescribed/stable thyroid, and topical medications are allowed.  Other medications may be approved on a case by case basis.

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 8 ½ weeks. 

    Inpatient Stays

    • Participants will admit for an inpatient stay at Prism Clinical Research 1 time.
    • The inpatient stay will last approximately 30 hours (1 overnight)

    Outpatient Visits

    • There are at total of 13 outpatient visits
    • The outpatient visits will last between approximately 30 minuts with the exception of the final visit which will last approximately 90 minutes.

     

    Compensation: Up to $1500.00

Please provide us with your contact information (below) and will get back to you as soon as possible.

If you have a general question, check Volunteer FAQ for an answer. If you're unsure of who to contact, please visit the Contact Us page.

Cancel